{
    "clinical_study": {
        "@rank": "13311", 
        "acronym": "DATA", 
        "arm_group": [
            {
                "arm_group_label": "ATAZANAVIR", 
                "arm_group_type": "Experimental", 
                "description": "The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal"
            }, 
            {
                "arm_group_label": "DARUNAVIR", 
                "arm_group_type": "Experimental", 
                "description": "The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal"
            }
        ], 
        "brief_summary": {
            "textblock": "A phase IV, prospective, multicenter , randomized open label, 48 weeks study to evaluate the\n      antiretroviral efficacy and safety of  atazanavir/ritonavir or  darunavir/ritonavir, each in\n      combination  with a fixed dose of tenofovir disoproxil fumarate- emtricitabine in\n      HIV-1-infected treatment-na\u00efve subjects with CD4  counts below 200 \u00b5L."
        }, 
        "brief_title": "Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-na\u00efve Subjects With Low CD4 Counts", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "HIV-1 Infection", 
            "Immunosuppression-related Infectious Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection", 
                "HIV Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Principal objective\n\n      To evaluate the virological efficacy and safety at week 48 of 2 regimens\n      atazanavir/ritonavir  (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in\n      combination  with a fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-na\u00efve subjects\n      with CD4  counts below 200 \u00b5L.\n\n      Secondary objectives\n\n        -  Proportion of subjets with virologic efficacy at week 24\n\n        -  Proportion of subjects with confirmed virologic failure at week 24 or later\n\n        -  Proportion of patients with virologic mutations\n\n        -  Evaluate the virologic effect in seminal fluid\n\n        -  To evaluate immunological response over time up to week 48\n\n        -  To assess plasma and seminal pharmacokinetics of the drugs in the treatment regimen at\n           week 4, 24, and 48\n\n        -  Correlate the pharmacokinetic properties  of the drugs with virologic outcome  in\n           plasma and semen at week 4 and 48\n\n        -  Correlate the free fraction (not bound to protein) of atazanavir and darunavir in\n           plasma and semen to virologic outcome\n\n        -  Evaluate the relationship of bilirubinemia with atazanavir\n\n        -  Change from baseline in fasting lipids, fasting glucose and insulin over time in the 2\n           arms\n\n        -  Compare adherence patient satisfaction  and sexual behaviour between the regimens\n\n      Methodology\n\n      This is a 48 week, multicentre, prospective, open label, phase IV, randomized. non\n      comparative, study.\n\n      Inclusion criteria\n\n        -  Male or female, aged > 18 years of age.\n\n        -  HIV-1 infection determined by a positive ELISA and confirmed by Western blot\n\n        -  Plasma HIV-RNA > 1 000 c/mL\n\n        -  CD4+T cell count < =200 cells/mm3 at the time of screening, or < =250 cells/mm3 if the\n           CD4 count was <200 cells/mm3 12 weeks before screening.\n\n        -  Women of childbearing potential must agree to use an effective method of barrier\n           contraception or have documented sterility.\n\n        -  Subjects must have medical insurance throught the Securite Sociale\n\n        -  Ability to understand and provide written informed consent.\n\n      Non-inclusion criteria\n\n        -  Acute opportunistic infection within the past two weeks\n\n        -  HIV-2 infection\n\n        -  pregnant woman\n\n        -  Any subject with drug resistance mutations at screening\n\n        -  Any subject with a grade 3 or greater clinical or laboratory adverse event at screening\n\n        -  Any subject who has received antiretoviral therapy except for prevention of mother to\n           child transmission and patients who has received post exposure prophylaxis for a  a\n           month or less\n\n        -  calculated creatinine clearance < 60/mL as estimated by the Cockcroft- Gault equation\n\n        -  Patients in the opinion of the investigator that are unlikley to be able to follow\n           study instructions\n\n        -  Any subject unable to take antiretroviral medication for whatever reason\n\n        -  Any subject taking a treatment or medication that is contraindicated when\n           co-administered with any arm or drug in the treatment.\n\n      Treatment:\n\n        -  Group 1 : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if TDF/FTc contre-indicated\n\n        -  atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg by day, 3 pills once a day,\n           during 48 weeks during a meal\n\n        -  Group 2 : DRV+ TDF/FTC (or ABC/3TC if TDF/FTc contre-indicated)\n\n        -  darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg by day, 4 pills once a day,\n           during 48 weeks during a meal\n\n      Primary Endpoints :\n\n        -  Proportion of patients with HIV-1 plasma viral load below 50 copies/mL at week 48 while\n           receiving their initial regimen\n\n        -  Proportion of patients experiencing grade 2-4 adverse clinical and laboratory events\n           including hematology, chemistry, lipids (total cholesterol, HDL cholesterol, LDL\n           cholesterol, triglycerides), glucose and insulin by week 48.\n\n      Secondary endpoints:\n\n        -  Proportion of patients with plasma HIV RNA  below 50 cp/mL at week 24\n\n        -  Proportion of patients with HIV RNA> 50 cp/mL at week 24 or later confirmed by a second\n           HIV RNA at least 14 days after the first test\n\n        -  Development of resistance mutations in subjects who have virologic failure testing at\n           24 weeks or later  tested by a genotypic resistance test\n\n        -  Evaluate the virologic effect in seminal fluid at baseline, W4 and W48 by change in HIV\n           RNA concentrations in semen over time\n\n        -  To evaluate immunological response over time up to week 48 in the 2 arms by CD4 cell\n           count ( W-4, W2,W4, W12, W36 and W48), differenciation and activation in T CD4 ( W2,W4,\n           W12, W24 and W48);  Change in lymphocyte subset reconsistution at week 48 compared to\n           baseline. ; Change in immunolgic markers of inflammations at weeks 2, 4,  12, 24, 48\n\n        -  To assess plasma and seminal pharmacokinetics of the drugs in the treatment regimen at\n           week 4, 24, and 48 through  residual concentrations ( C min) of antiretroviral drugs at\n           W4, W24, and W48\n\n        -  Atazanavir and darunavir (plasma and seminal) drug concentrations and coorelation with\n           adverse clinical and laboratory events.\n\n        -  Evaluate the relationship of bilirubinemia with atazanavir pharmacokinetics (Cmin)\n\n        -  Evolution of lipid, glucose and insulin parameters from baseline to weeks 24 and 48\n\n        -  Adherence to regimen,  patient satisfaction and sexual behaviour between the regimens\n           at W2,W24 and W48 mesured by ( mettre ref)\n\n        -  Evolution of anthropomorphic measurements from baseline to weeks 24, 48.\n\n      Substudies Brief description (2 lines maximum) and person in charge of the substudy\n\n        -  Immunologic substudy ( Pr Brigitte Autran) : Change in immunolgic markers of\n           inflammations at weeks 2, 4,  12, 24, 48  and change in lymphocyte subset\n           reconsistution at week 48 compared to baseline.\n\n        -  Pharmacologic substudy ( Dr Gilles Peytavin) : To assess plasma and seminal\n           pharmacokinetics of the drugs in the treatment regimen at week 4, 24, and 48 through\n           residual concentrations ( C min) of antiretroviral drugs at W4, W24, and W48\n\n        -  Virologic substudy ( Dr Anne Genevi\u00e8ve Marcelin) : Evaluate the virologic effect in\n           seminal fluid at baseline, W4 and W48\n\n        -  Behaviour substudy ( Dr France Lert) : Compare adherence  patient satisfaction and\n           sexual behaviour between the regimens at W2,W24 and W48\n\n      Estimated enrolment: 120 subjects (60 per group) randomly assigned 1:1"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Male or female, aged > 18 years of age\n\n          -  HIV-1 infection determined by a positive ELISA and confirmed by Western blot\n\n          -  Plasma HIV-RNA > 1 000 c/mL\n\n          -  CD4+T cell count < =200 cells/mm3 at the time of screening, or < =250 cells/mm3 if\n             the CD4 count was <200 cells/mm3 12 weeks before screening\n\n          -  Women of childbearing potential must agree to use an effective method of barrier\n             contraception or have documented sterility\n\n          -  Subjects must have medical insurance throught the Securite Sociale\n\n          -  Ability to understand and provide written informed consent\n\n        Exclusion Criteria\n\n          -  Acute opportunistic infection within the past two weeks\n\n          -  HIV-2 infection\n\n          -  Pregnant woman\n\n          -  Any subject with drug resistance mutations at screening\n\n          -  Any subject with a grade 3 or greater clinical or laboratory adverse event at\n             screening\n\n          -  Any subject who has received antiretoviral therapy except for prevention of mother to\n             child transmission and patients who has received post exposure prophylaxis for a  a\n             month or less\n\n          -  Calculated creatinine clearance < 60/mL as estimated by the Cockcroft- Gault equation\n\n          -  Patients in the opinion of the investigator that are unlikley to be able to follow\n             study instructions\n\n          -  Any subject unable to take antiretroviral medication for whatever reason\n\n          -  Any subject taking a treatment or medication that is contraindicated when\n             co-administered with any arm or drug in the treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928407", 
            "org_study_id": "IMEA 040-DATA"
        }, 
        "intervention": [
            {
                "arm_group_label": "DARUNAVIR", 
                "description": "The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules", 
                "intervention_name": "DARUNAVIR", 
                "intervention_type": "Drug", 
                "other_name": "Prezista"
            }, 
            {
                "arm_group_label": "ATAZANAVIR", 
                "description": "The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules", 
                "intervention_name": "ATAZANAVIR", 
                "intervention_type": "Drug", 
                "other_name": "REYATAZ"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atazanavir", 
                "Darunavir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "naives, CD4 < 200 cell/mm3, Atazanavir, Darunavir", 
        "lastchanged_date": "August 20, 2013", 
        "location": [
            {
                "contact": {
                    "email": "andre.cabie@chu-fort-de-france.fr", 
                    "last_name": "Andr\u00e9 AC CABIE, PhD", 
                    "phone": "+33.5.96.55.23.01"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort-de-france", 
                        "country": "France", 
                        "state": "Martinique", 
                        "zip": "97261"
                    }, 
                    "name": "Hopital Zobda Quitman"
                }, 
                "investigator": {
                    "last_name": "Andr\u00e9 AC CABIE, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "juliette.gerbe@ch-argenteuil.fr", 
                    "last_name": "Juliette JG GERBE", 
                    "phone": "+33.1.34.23.22.18"
                }, 
                "facility": {
                    "address": {
                        "city": "Argenteuil", 
                        "country": "France", 
                        "zip": "95107"
                    }, 
                    "name": "Centre Hospitalier D'Argenteuil"
                }, 
                "investigator": {
                    "last_name": "Virginie VM MASSE, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "c1bourdeaux@chu-besancon.fr", 
                    "last_name": "V\u00e9ronique VB BOURDEAUX, PhD", 
                    "phone": "+33.3.81.21.85.33"
                }, 
                "facility": {
                    "address": {
                        "city": "Besancon", 
                        "country": "France", 
                        "zip": "25000"
                    }, 
                    "name": "Hopital Saint-Jacques"
                }, 
                "investigator": {
                    "last_name": "Bruno BH HOEN, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gaelle.obenga@avc.aphp.fr", 
                    "last_name": "Ga\u00eblle GO OBENGA, PhD", 
                    "phone": "+33.1.48.95.54.21"
                }, 
                "facility": {
                    "address": {
                        "city": "Bobigny", 
                        "country": "France", 
                        "zip": "93000"
                    }, 
                    "name": "Hopital Avicenne"
                }, 
                "investigator": {
                    "last_name": "Olivier OB BOUCHAUD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mufide.kahraman@jvr.aphp.fr", 
                    "last_name": "Mufide MK KAHRAMAN", 
                    "phone": "+33.1.48.02.63.11"
                }, 
                "facility": {
                    "address": {
                        "city": "Bondy", 
                        "country": "France", 
                        "zip": "93143"
                    }, 
                    "name": "Hopital Jean Verdier"
                }, 
                "investigator": {
                    "last_name": "Vincent VJ JEANTILS, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sabrina.caldato@chu-bordeaux.fr", 
                    "last_name": "Sabrina SC CALDATO", 
                    "phone": "+33.5.56.79.57.33"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "zip": "33075"
                    }, 
                    "name": "Hopital Saint-Andre"
                }, 
                "investigator": {
                    "last_name": "Patrick PM MERCIE, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "feret-p@chu-caen.fr", 
                    "last_name": "Philippe PF FERET", 
                    "phone": "+33.2.31.06.50.87"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14033"
                    }, 
                    "name": "Chu Cote de Nacre"
                }, 
                "investigator": {
                    "last_name": "Renaud RV VERDON, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "feng.zeng@lmr.aphp.fr", 
                    "last_name": "Feng FZ ZENG", 
                    "phone": "+33.1.47.60.61.84"
                }, 
                "facility": {
                    "address": {
                        "city": "Colombes", 
                        "country": "France", 
                        "zip": "92700"
                    }, 
                    "name": "Hopital Louis Mourier"
                }, 
                "investigator": {
                    "last_name": "Emmanuel EM MORTIER, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sandrine.gohier@chu-dijon.fr", 
                    "last_name": "Sandrine ST GOHIER", 
                    "phone": "+33.3.80.29.36.31"
                }, 
                "facility": {
                    "address": {
                        "city": "Dijon", 
                        "country": "France", 
                        "zip": "21034"
                    }, 
                    "name": "Hopital Le Bocage"
                }, 
                "investigator": {
                    "last_name": "Lionel LP PIROTH, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "huguette.berthe@rpc.aphp.fr", 
                    "last_name": "Huguette HB BERTHE", 
                    "phone": "+33.1.47.10.46.65"
                }, 
                "facility": {
                    "address": {
                        "city": "Garches", 
                        "country": "France", 
                        "zip": "92380"
                    }, 
                    "name": "Hopital Raymond Poincare"
                }, 
                "investigator": {
                    "last_name": "Pierre PT DE TRUCHIS, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hjmpu@chd-vendee.fr", 
                    "last_name": "Isabelle IS SUAUD", 
                    "phone": "+33.2.51.37.49.66"
                }, 
                "facility": {
                    "address": {
                        "city": "La Roche Sur Yon", 
                        "country": "France", 
                        "zip": "85925"
                    }, 
                    "name": "C.H.D de Vendee"
                }, 
                "investigator": {
                    "last_name": "Philippe PP PERRE, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "claire.genet@unilim.fr", 
                    "last_name": "Claire CG GENET, PhD", 
                    "phone": "+33.5.55.05.66.44"
                }, 
                "facility": {
                    "address": {
                        "city": "Limoges", 
                        "country": "France", 
                        "zip": "87000"
                    }, 
                    "name": "Hopital Dupuytren"
                }, 
                "investigator": {
                    "last_name": "Claire CG GENET, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alena.ivanova@mail.ap-hm.fr", 
                    "last_name": "Alena AI IVANOVA", 
                    "phone": "+33.4.91.74.61.63"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13274"
                    }, 
                    "name": "Hopital Sainte-Marguerite"
                }, 
                "investigator": {
                    "last_name": "Isabelle IM POIZOT-MARTIN, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ali.kara@ch-melun.fr", 
                    "last_name": "Ali AK KARA, PhD", 
                    "phone": "+33.1.64.71.60.96"
                }, 
                "facility": {
                    "address": {
                        "city": "Melun", 
                        "country": "France", 
                        "zip": "77011"
                    }, 
                    "name": "Centre Hospitalier de Melun"
                }, 
                "investigator": {
                    "last_name": "Ali AK KARA, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "serini.ma@chu-nice.fr", 
                    "last_name": "Marie-Ange MS SERINI", 
                    "phone": "+33.4.92.03.90.22"
                }, 
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06202"
                    }, 
                    "name": "Hopital L'Archet"
                }, 
                "investigator": {
                    "last_name": "Jacques JD DURANT, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.lupin@psl.aphp.fr", 
                    "last_name": "Catherine CL LUPIN", 
                    "phone": "+33.1.42.16.10.95"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75651"
                    }, 
                    "name": "Hopital Pitie-Salpetriere"
                }, 
                "investigator": {
                    "last_name": "Anne AS SIMON, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fatima.touam@nck.aphp.fr", 
                    "last_name": "Fatima FT TOUAM", 
                    "phone": "+33.1.44.49.40.28"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75015"
                    }, 
                    "name": "Hopital Necker"
                }, 
                "investigator": {
                    "last_name": "Claudine CD DUVIVIER, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patricia.bourse@psl.aphp.fr", 
                    "last_name": "Patricia PB BOURSE", 
                    "phone": "+33.1.42.16.02.93"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75013"
                    }, 
                    "name": "Hopital Pitie-Salpetriere"
                }, 
                "investigator": {
                    "last_name": "Christine CK KATLAMA, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "maguy.parrinello@lrb.aphp.fr", 
                    "last_name": "Maguy MP PARRINELLO", 
                    "phone": "+33.1.49.95.63.43"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75010"
                    }, 
                    "name": "Hopital Lariboisiere"
                }, 
                "investigator": {
                    "last_name": "Jean-Fran\u00e7ois JB BERGMANN, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "erika.bourzam@egp.aphp.fr", 
                    "last_name": "Erika EB BOURZAM", 
                    "phone": "+33.1.56.09.33.03"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75908"
                    }, 
                    "name": "Hopital Europeen Georges Pompidou"
                }, 
                "investigator": {
                    "last_name": "Laurence LW WEISS, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zelie.julia@bch.aphp.fr", 
                    "last_name": "Z\u00e9lie ZJ JULIA", 
                    "phone": "+33.1.40.25.70.57"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75018"
                    }, 
                    "name": "Hopital Bichat"
                }, 
                "investigator": {
                    "last_name": "V\u00e9ronique VJ JOLY, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jean-luc.lagneau@sat.aphp.fr", 
                    "last_name": "Jean-Luc JL LAGNEAU", 
                    "phone": "+33.1.49.28.24.86"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75012"
                    }, 
                    "name": "Hopital Saint Antoine"
                }, 
                "investigator": {
                    "last_name": "Nadia NV VALIN, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "laurence.slama@tnn.aphp.fr", 
                    "last_name": "Laurence LS SLAMA, PhD", 
                    "phone": "+33.1.56.01.74.36"
                }, 
                "contact_backup": {
                    "email": "nadege.velazquez@tnn.aphp.fr", 
                    "last_name": "Nad\u00e8ge NV VELAZQUEZ", 
                    "phone": "+33.1.56.01.74.36"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75020"
                    }, 
                    "name": "Hopital Tenon"
                }, 
                "investigator": {
                    "last_name": "Laurence LS SLAMA, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marie-pierre.pietri@cch.aphp.fr", 
                    "last_name": "Marie-Pierre MP PIETRI", 
                    "phone": "+33.1.58.41.21.34"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75674"
                    }, 
                    "name": "Hopital Cochin"
                }, 
                "investigator": {
                    "last_name": "Dominique DS SALMON, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "recherche.clinique@ch-perpignan.fr", 
                    "last_name": "Martine MM MALET", 
                    "phone": "+33.4.68.61.61.43"
                }, 
                "facility": {
                    "address": {
                        "city": "Perpignan", 
                        "country": "France", 
                        "zip": "66046"
                    }, 
                    "name": "Hopital Saint-Jean Roussillon"
                }, 
                "investigator": {
                    "last_name": "Hugues HA AUMAITRE, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "martine.deschaud@ch-pontoise.fr", 
                    "last_name": "Martine MD DESCHAUD", 
                    "phone": "+33.1.30.75.47.24"
                }, 
                "facility": {
                    "address": {
                        "city": "Pontoise", 
                        "country": "France", 
                        "zip": "95303"
                    }, 
                    "name": "Hopital Rene Dubos"
                }, 
                "investigator": {
                    "last_name": "Laurent LB BLUM, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gclavere@ch-annecy.fr", 
                    "last_name": "Ga\u00eblle GC CLAVERE", 
                    "phone": "+33.4.50.63.67.93"
                }, 
                "facility": {
                    "address": {
                        "city": "Pringy", 
                        "country": "France", 
                        "zip": "74374"
                    }, 
                    "name": "C.H.R.A"
                }, 
                "investigator": {
                    "last_name": "Jean-Pierre JB BRU, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "patricia.fischer@chru-strasbourg.fr", 
                    "last_name": "Patricia PF FISCHER", 
                    "phone": "+33.3.69.55.05.01"
                }, 
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67000"
                    }, 
                    "name": "Hopital Civil"
                }, 
                "investigator": {
                    "last_name": "David DR REY, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "svandamme@ch-tourcoing.fr", 
                    "last_name": "Sylvie SV VANDAMME"
                }, 
                "facility": {
                    "address": {
                        "city": "Tourcoing", 
                        "country": "France", 
                        "zip": "59208"
                    }, 
                    "name": "Hopital Gustave Dron"
                }, 
                "investigator": {
                    "last_name": "Yazdan YY YAZDANPANAH, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "g.fajole@chu-tours.fr", 
                    "last_name": "Ga\u00eblle GF FAJOLE", 
                    "phone": "+33.2.47.47.37.14"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37044"
                    }, 
                    "name": "Hopital Bretonneau"
                }, 
                "investigator": {
                    "last_name": "Louis LB BERNARD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-na\u00efve Subjects With CD4counts Below 200 \u00b5L.", 
        "overall_contact": {
            "email": "aida.benalycherif@gmail.com", 
            "last_name": "A\u00efda AB BENALYCHERIF", 
            "phone": "+33.1.40.25.63.65"
        }, 
        "overall_contact_backup": {
            "email": "karine.amat@hotmail.fr", 
            "last_name": "Karine KA AMAT", 
            "phone": "+33.1.40.25.63.52"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital TENON", 
                "last_name": "Laurence LS SLAMA, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e - Fondation Internationale L\u00e9on M'Ba", 
                "last_name": "Roland RL LANDMAN, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the virological efficacy and safety at week 48 of 2 regimens atazanavir/ritonavir  (ATZ/r) 300/100 mg or darunavir/ritonavir (DRV/r) 800/100 mg, each in combination  with a fixed-dose of tenofovir/emtracitabine in HIV-1 treatment-na\u00efve subjects with CD4  counts below 200 \u00b5L", 
            "measure": "Viral load of HIV-1 < 50 cp/ml", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928407"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tProportion of subjets with virologic efficacy (viral load of HIV-1 <50 cp/ml)", 
                "measure": "\u2022 Proportion of subjets with virologic efficacy", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "\u2022\tProportion of subjects with confirmed virologic failure (viral load > 50 cp/ml on 2 consecutive mesures)", 
                "measure": "\u2022 Proportion of subjects with confirmed virologic failure", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "\u2022\tEvaluate the viral load of HIV-1 at week 0, week 4 and week 48 on the seminal fluid (substudy)", 
                "measure": "Viral lod of HIV-1 on seminal fluid", 
                "safety_issue": "Yes", 
                "time_frame": "W00,W4 et W48"
            }, 
            {
                "description": "\u2022\tEvaluate the immunologic response by the CD4 mesearement at W-4,W2,W4,W12,W24 and W48", 
                "measure": "Immunologic response", 
                "safety_issue": "Yes", 
                "time_frame": "W-4,W2,W4,W12,W24 and W48"
            }, 
            {
                "description": "At the end of the study, in a central lab, we will measure some inflammation and activation markers (CD69, HLA-DR, CD38, annexine V, IL-6, CD14s, IL-7 plasma) of lymphocytes CD4 and CD8(with the plasmatheque collected during the study)", 
                "measure": "Differenciation and activation of lymphocytes", 
                "safety_issue": "Yes", 
                "time_frame": "W0,W2,W4,W12,W24 and W48"
            }, 
            {
                "description": "Measure of drugs (atazanir and darunavir) concentration (24 hours after taking treatment)in plasma at week 4, 24, and 48", 
                "measure": "Pharmacokinetics evaluation of the drugs in plasma", 
                "safety_issue": "Yes", 
                "time_frame": "W4,W24 and W48"
            }, 
            {
                "description": "Measure of drugs (atazanir and darunavir) concentration (24 hours after taking treatment)in semen at week 4 and 48", 
                "measure": "Pharmacokinetic evaluation of the drugs in semen", 
                "safety_issue": "Yes", 
                "time_frame": "W4 and W48"
            }, 
            {
                "description": "Evaluate the relationship of the evolution of the measure of bilirubinemia (collected during study) with the concentration of atazanavir in blood", 
                "measure": "\u2022 Evaluate the relationship of bilirubinemia with atazanavir", 
                "safety_issue": "Yes", 
                "time_frame": "W4 and W48"
            }, 
            {
                "description": "\u2022\tChange from baseline in fasting lipids, fasting glucose and insulin over time in the 2 arms", 
                "measure": "Fasting glucose, lipids and insulin", 
                "safety_issue": "Yes", 
                "time_frame": "W48"
            }, 
            {
                "description": "Evaluate the clinic and biologic tolerance between the 2 regimens (adverse event and some biologic measure will be collected for this evaluation).\nWe will see in two arms if there are more adverse event or biological event.", 
                "measure": "Clinic and biologic tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "W48"
            }, 
            {
                "description": "\u2022\tCompare sexual behaviour between the regimens (substudy with a questionnary)", 
                "measure": "Sexual behaviour", 
                "safety_issue": "Yes", 
                "time_frame": "W0,W24 et W48"
            }, 
            {
                "description": "\u2022\tCompare adherence patient satisfaction between the regimens (with questionnary)", 
                "measure": "Adherence patient satisfaction", 
                "safety_issue": "No", 
                "time_frame": "W2,W24 et W48"
            }
        ], 
        "source": "Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e - Fondation Internationale L\u00e9on M'Ba", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e - Fondation Internationale L\u00e9on M'Ba", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}